Selection of a phage-displayed peptide recognized by monoclonal antibody directed blocking the site of hepatitis C virus E2 for human CD81.
J Microbiol Methods
; 68(3): 601-4, 2007 Mar.
Article
en En
| MEDLINE
| ID: mdl-17178166
The human CD81 (hCD81) molecule has been identified as a putative receptor for hepatitis C virus (HCV). HCV envelope glycoprotein 2 (E2) most likely plays a pivotal role in binding to host cells by interacting with the hCD81 molecule. In this study, a phage-displayed peptide library was used to select small peptides with anti-hCD81 monoclonal antibody JS-81. The output/input ratio of phages increased about 91 fold after the third round of selection. Eight of the 30 phage clones selected from the phage library showed specific binding to the anti-hCD81 by enzyme linked immunosorbent assay (ELISA). Competitive inhibition test further demonstrated that HCV E2 could significantly inhibit the binding of a positive phage clone to anti-hCD81 JS-81. Exogenous small peptide ATWVCGPCT contained by the positive phage clones showed aligned with the hCD81 sequence from 153-161 by sequence analyses. These results suggest that the selected ATWVCGPCT is a novel hCD81-like small peptide, which can block the binding site of HCV E2 for hCD81. It may be of further application on development of antiviral agents targeting the stage of HCV entry.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Péptidos
/
Antígenos CD
/
Proteínas del Envoltorio Viral
/
Biblioteca de Péptidos
/
Anticuerpos Monoclonales
Tipo de estudio:
Evaluation_studies
Límite:
Humans
Idioma:
En
Revista:
J Microbiol Methods
Año:
2007
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Países Bajos